the xanthine oxidase inhibitor
The first-line urate-lowering therapy for gout and prophylaxis against tumour lysis syndrome.
- Mechanism: Inhibits Xanthine Oxidase, preventing conversion of Hypoxanthine Xanthine Uric Acid.
indications
- Gout: Chronic management (Target Uric Acid µmol/L).
- Initiation: Start low (100 mg) to prevent flares. Cover with Colchicine/NSAID.
- Tumour Lysis Syndrome: Prophylaxis in intermediate-risk patients. (Not effective for existing high uric acid - see Rasburicase).
dosing
- Renal Adjustment: Active metabolite (Oxypurinol) accumulates in renal failure.
- Standard: 100-300 mg daily. Max 800-900 mg.
adverse effects
- Allopurinol Hypersensitivity Syndrome (AHS/DRESS):
- Risk: High mortality. Rash, Eosinophilia, Hepatitis, AKI.
- Genetics: HLA-B*5801 (Han Chinese, Thai, Korean, African descent). Screening recommended in high-risk groups.
- Drug Interaction: Azathioprine / 6-MP.
- Danger: Allopurinol blocks metabolism of Azathioprine Fatal Bone Marrow Suppression.
- Action: Reduce Azathioprine dose by 75% or switch urate agent.